Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05382156 · ClinicalTrials.gov registry record
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
A clinical trial of Endogenous Cushing's Syndrome, sponsored by Recordati Group.
- Active
- Registry status
- 206
- Enrollment target
- 20
- Study locations
NCT05382156: Active study of Endogenous Cushing's Syndrome, sponsored by Recordati Group.
NCT05382156 is a study of Endogenous Cushing's Syndrome that is active but no longer recruiting, run by Recordati Group. The registered enrollment target is 206 participants. The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05382156, a study of Endogenous Cushing's Syndrome, is active but no longer recruiting, sponsored by Recordati Group.
- ACTIVE NOT RECRUITING
- Registry status
- 206 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome
Primary Outcome
Number of participants with Adverse Events and Serious Adverse Events
Conditions Studied
Interventions
- DRUG Osilodrostat
Study Locations (20)
Other
- Hôpital Haut-Lévêque - Bordeaux
- Hospices Civiles de Lyon - Bron
- CHU de Grenoble site Nord - Grenoble
- Groupement Hospitalier Sud - Hôpital Bicêtre - Le Kremlin-Bicêtre
- Hopital Claude Huriez - CHRU Lille - Lille
New York
- NYU Grossman School of Medicine - New York
- Memorial Sloan-Kettering Cancer Center (MSKCC) - New York - New York
Arizona
- Barrow Neurological Institute - Phoenix
Georgia
- Emory University School - Atlanta
Illinois
- Northwestern University - Chicago
Indiana
- Indiana University Schl-med - Indianapolis
Kentucky
- St Elizabeth Physicians - Covington
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 206 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2027-08 |
What the registry record for NCT05382156 still lists
NCT05382156 is an observational study that tracks outcomes without assigning an intervention. The registered 206 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Endogenous Cushing's Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Osilodrostat is the first listed.
NCT05382156 names 20 study sites across 15 states, led by Other, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT05382156 about?
NCT05382156 is a clinical study titled "Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome". This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with osilodrostat for endogenous Cushing's Syndrome
What is the current status of trial NCT05382156?
This trial is currently active not recruiting. The enrollment target is 206 participants. The study started on 2022-06-13. Estimated completion is 2027-08.
What conditions does trial NCT05382156 study?
This clinical trial studies the following conditions: Endogenous Cushing's Syndrome.
What interventions are being tested in trial NCT05382156?
The interventions under investigation include: Osilodrostat (DRUG).
Who is sponsoring clinical trial NCT05382156?
This trial is sponsored by Recordati Group, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05382156 being conducted?
This trial has 20 study locations across Arizona, Georgia, Illinois, Indiana, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endogenous Cushing's Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03373968 · 206 participants · Phase 2
Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- NCT03550391 · 206 participants · Phase 3
Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases
- NCT04757116 · 206 participants · NA
Post-Market Study to Assess iTind Safety in Comparison to UroLift
- NCT05675865 · 206 participants · NA
Cryoablation for Monomorphic Ventricular Tachycardia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI